Table 3.
Summary of patient immunotherapy-related adverse events by patient group
| Group | All | P value* | ||
| Ctrl | IBD | |||
| N (%) | N (%) | N (%) | ||
| irAEs† | ||||
| No | 73 (48.67) | 11 (36.67) | 84 (46.67) | 0.32 |
| Yes | 77 (51.33) | 19 (63.33) | 96 (53.33) | |
| ICI stop reason | ||||
| Colitis | 6 (4) | 7 (23.33) | 13 (7.22) | 0.04 |
| Disease progression | 51 (34) | 8 (26.67) | 59 (32.78) | |
| Other irAE | 23 (15.33) | 6 (20) | 29 (16.11) | |
| Death | 32 (21.33) | 4 (13.33) | 36 (20) | |
| Complete remission | 1 (0.67) | 0 (0) | 1 (0.56) | |
| Still receiving | 23 (15.33) | 5 (16.67) | 28 (15.56) | |
| Infection | 5 (3.33) | 0 (0) | 5 (2.78) | |
| Treatment break | 9 (6) | 0 (0) | 9 (5) | |
| ICI stop reason (condensed) | ||||
| N/A (still receiving) | 23 (15.33) | 5 (16.67) | 28 (15.56) | |
| All other reasons | 98 (65.33) | 12 (40) | 110 (61.11) | 0.006 |
| irAE (including imDC) | 29 (19.33) | 13 (43.33) | 42 (23.33) | |
IBD and control cohorts were propensity score matched by cancer type, cancer mediation, and age.
*P values by Fisher’s exact test.
†ICI colitis and ICI diarrhea were analyzed as time-to-event endpoints and were not included in this table.
IBD, inflammatory bowel disease; ICI, immune checkpoint inhibitor; imDC, immune-mediated diarrhea and colitis; irAE, immune-related adverse events.